BPMC News and Press, Blueprint Medicines Corporation From 05/03/21

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio. Discovered by CStone's part...

Blueprint Medicines Corporation (BPMC) Q1 2021 Earnings Conference Call April 29, 2021, 2021 08:30 ET Company Participants Kristin Hodous - Senior Manager, Investor Relations Jeff Albers - Chief Executive Officer Christy Rossi - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mi...

Blueprint Medicines  (BPMC): Q1 GAAP EPS of -$1.72 beats by $0.11.Revenue of $21.58M (+249.8% Y/Y) beats by $3.63M.Press Release For further details see: Blueprint Medicines  EPS beats by $0.11, beats on revenue

Blueprint Medicines Reports First Quarter 2021 Financial Results -- 7 research- and clinical-stage programs highlighted at AACR, including recently nominated development candidate with best-in-class potential targeting CDK2 -- -- GAVRETO® (pralsetinib) becomes the first...

Blueprint Medicines  (NASDAQ:BPMC) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is -$1.83 and the consensus Revenue Estimate is $17.95M.Over the last 1 year, BPMC has beaten EPS estimates 25% of the time and has beate...

Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021 PR Newswire CAMBRIDGE, Mass. , April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference c...

While the market is hitting all-time highs, shares of the Nasdaq Biotechnology ETF (NASDAQ: IBB) are trading essentially flat year-to-date, down just over 15% from their peak. Down 11% since the beginning of the year, but up just less than fivefold over the past five years , Bluep...

Blueprint Medicines (BPMC) announces data from its systemic mastocytosis ((SM)) program at AACR Annual Meeting 2021.The presentations focus on data of Ayvakit (avapritinib) in advanced SM, the impact of Ayvakit on skin manifestations of SM, and Phase 1 trial data for BLU-263.Highlights from P...

Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021 -- 75% confirmed ORR, with all responses ongoing, in PATHFINDER trial of AYVAKIT in advanced SM -- -- New patient-reported outcomes data from PATHFINDER trial show AYV...

Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021 -- Preclinical data presented at AACR highlight four precision therapies with first- or best-in-class potential -- -- IND application cleared by F...